+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease

Controlled multicentre therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn's disease

British Medical Journal 295(6597): 517-520

Between 1 September 1980 and 31 August 1983, 352 patients with inactive or mildly active Crohn's disease but not taking drug treatment apart from sulphasalazine were entered from 40 hospitals into a prospective trial to assess the effects of two different diets on disease activity over two years. One hundred and sixty two patients were randomly allocated to take a diet unrestricted in sugar and low in fibre and 190 to a diet with little or no sugar and high in unrefined carbohydrate. No clear difference in clinical course was detected among patients who accepted the two different types of dietary advice.(author)

(PDF emailed within 0-6 h: $19.90)

Accession: 001554969

Download citation: RISBibTeXText

PMID: 2822203

DOI: 10.1136/bmj.295.6597.517

Related references

Treatment of Crohn's disease with an unrefined-carbohydrate, fibre-rich diet. British Medical Journal 2(6193): 764-766, 1979

Treatment of active Crohn's disease by exclusion diet: East anglian multicentre controlled trial. Lancet (North American Edition) 342(8880): 1131-1134, 1993

Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Disease Study Group). Scandinavian Journal of Gastroenterology 31(8): 778-785, 1996

Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's disease: A randomized controlled multicenter trial. Scandinavian Journal of Gastroenterology 31(8): 778-785, 1996

Effect on 24-h energy expenditure of a moderate-fat diet high in monounsaturated fatty acids compared with that of a low-fat, carbohydrate-rich diet: a 6-mo controlled dietary intervention trial. American Journal of Clinical Nutrition 85(4): 1014-1022, 2007

PWE-364 High fibre diet, low fibre diet or habitual diet for the prevention of radiation-induced toxicity in pelvic cancer: a multi-centre randomised controlled trial. Gut 64(Suppl 1): A370.2-A371, 2015

Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial. Bmj Open Gastroenterology 3(1): E000123-E000123, 2017

A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 59(6): 760-766, 2010

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet, 2017

Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatrica 93(3): 327-335, 2004

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Alimentary Pharmacology & Therapeutics 23(8): 1117-1125, 2006

A high-fibre bean-rich diet versus a low-carbohydrate diet for obesity. Journal of Human Nutrition and Dietetics 27 Suppl 2: 109-116, 2014

Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. European Journal of Gastroenterology & Hepatology 16(1): 47-54, 2004

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Lancet. Gastroenterology & Hepatology 2(11): 785-792, 2017

Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. Lancet. Gastroenterology & Hepatology 1(4): 273-282, 2017